Proton pump inhibitors and risk of hepatocellular carcinoma : a case-control study in Taiwan
| Journal | Volume 76 - 2013 |
| Issue | Fasc.3 - Letters |
| Author(s) | Shih-Wei Lai, Kuan-Fu Liao, Hsueh-Chou Lai, Cheng-Li Lin, Fung-Chang Sung |
| Full article |
 VIEW FREE PDF |
| (1) School of Medicine, (3) Graduate Institute of Integrated Medicine, (6) School of Chinese Medicine, and (8) Department of Public Health, China Medical University, Taichung, Taiwan ; (2) Department of Family Medicine, 7Department of Internal Medicine, and (9) Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan ; (4) Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan ; (5) Department of Health Care Administration, Central Taiwan University of Science and Technology, Taichung, Taiwan. |
|
Proton pump inhibitors (PPIs) are effective drugs that are frequently used for the management of peptic ulcer and gastro-esophageal reflux disease as well as for the elimination of Helicobacter infection. However, the long-term use of PPIs has been shown to cause hypergas- trinemia (1,2). Experimental and clinical studies have also shown that hypergastrinemia might correlate with the risk for gastro-intestinal cancers, with the exception of hepatocellular carcinoma (HCC) (3-5). Few studies on the association between PPIs use and HCC risk are avail- able. |
|
© Acta Gastro-Enterologica Belgica. PMID 24261033 |
